TD Cowen Initiates Coverage on Cyclerion Therapeutics (NASDAQ:KRSA)

Investment analysts at TD Cowen started coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA) in a research report issued on Monday, Briefing.com reports. The brokerage set a “buy” rating on the stock.

A number of other brokerages have also issued reports on KRSA. UBS Group started coverage on shares of Cyclerion Therapeutics in a research note on Friday. They set a “buy” rating and a $55.00 price target on the stock. Zacks Research upgraded shares of Cyclerion Therapeutics to a “hold” rating in a research report on Wednesday, September 9th. Finally, Stifel Nicolaus assumed coverage on Cyclerion Therapeutics in a report on Monday. They issued a “buy” rating and a $43.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $49.00.

Cyclerion Therapeutics Stock Performance

Shares of NASDAQ:KRSA traded down $1.12 during trading on Monday, reaching $30.79. The stock had a trading volume of 4,422 shares, compared to its average volume of 313,500. The stock has a market capitalization of $20.63 million, a P/E ratio of -2.65 and a beta of 1.75. Cyclerion Therapeutics has a one year low of $7.19 and a one year high of $59.36.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for serious diseases of the central nervous system. The company has concentrated on therapies designed to influence the nitric oxide–soluble guanylate cyclase signaling pathway, which may play a role in neurological and other debilitating conditions.

Cyclerion’s lead development program was IW-6463, an oral, central nervous system-penetrant soluble guanylate cyclase stimulator investigated for potential use in neurodegenerative diseases, including Alzheimer’s disease and amyotrophic lateral sclerosis.